Page last updated: 2024-11-06

propionohydroxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Propionohydroxamic acid (PHA) is a hydroxamic acid derivative of propionic acid. It is a white solid that is soluble in water and ethanol. PHA is a potent inhibitor of histone deacetylases (HDACs), enzymes that regulate gene expression by removing acetyl groups from histone proteins. Inhibition of HDACs leads to increased acetylation of histones, which in turn can activate gene transcription. PHA has been shown to have a variety of biological activities, including anti-cancer, anti-inflammatory, and neuroprotective effects. PHA is typically synthesized by reacting propionyl chloride with hydroxylamine. PHA is studied for its potential therapeutic uses in a variety of diseases, including cancer, Alzheimer's disease, and diabetes. It is also being investigated as a potential treatment for inflammatory bowel disease and other inflammatory conditions.'

Cross-References

ID SourceID
PubMed CID75743
CHEMBL ID4303316
MeSH IDM0111380

Synonyms (25)

Synonym
unii-9k8td4emp0
9k8td4emp0 ,
propionohydroxamic acid
propionhydroxamic acid
n-hydroxypropionamide
propiohydroxamic acid
usaf cs-502
einecs 219-946-2
AKOS000191131
2580-63-4
n-hydroxypropanamide
BBL011342
STL146432
propanamide, n-hydroxy-
propionohydroximic acid
RSIPQHOWTCNEBI-UHFFFAOYSA-N
DTXSID30180460
mfcd00154630
ethyl hydroximic acid
zami-633
CHEMBL4303316
Q27272667
XGM ,
EN300-211443
PD061922

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A low dosage propiono-hydroxamic acid (PHA) treatment, 60 mg twice a day for 7 days and then 60 mg/day, was used in 15 patients affected with neurourologic pathologies for 3 months."( Low dosage treatment with propiono-hydroxamic acid in paraplegic patients.
Carone, R; Casetta, G; Piana, P; Tizzani, A; Vercelli, D, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (87.50)18.7374
1990's1 (6.25)18.2507
2000's1 (6.25)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.16 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]